Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
30 slides from Innate Pharma Sa Class A's conference presentation, Jan 14, 2025
Slide 1: J.P. Morgan Health Care Conference
J.P. Morgan Health Care Conference San Francisco, CA Jonathan Dickinson │CEO Yannis Morel │EVP COO Sonia Quaratino │EVP CMO Arvind Sood │EVP US Ops January 14th, 2025
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Building on a Foundation of World Class Antibody Engineering Expertise and Clinical Execution
Innate Pharma: Building on a Foundation of World Class Antibody Engineering Expertise and Clinical Execution Antibody Engineering Excellence Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Leveraging our expertise in
Slide 4: 2024: A strong year of Publications in high impact journals
2024: A strong year of Publications in high impact journals Vivier et al, 2024. Fenis et al, 2024. Natural killer cell therapies New immune cell engagers for cancer immunotherapy Demaria et al, 2024. Rebuffet et al., 2024 A tetraspecific engager armed with a non- High-dimensional single-cell analysi
Slide 5: 2024: A Year of Strong R&D Execution
2024: A Year of Strong R&D Execution Lacutamab: FDA interactions IPH6501: IPH4502: leading to Accelerated Phase 1 initiated IND Cleared by FDA Approval opportunity 5
Slide 6: 2025: Focus on Strategic Growth Pillars
2025: Focus on 3 Strategic Growth Pillars NK-cell engagers Antibody Drug Conjugates Current Late-Stage Assets • IPH6501 (CD20) ANKET® Phase 1 • IPH4502 (Nectin-4) IND cleared, • Lacutamab positive Phase 2 data, Phase 1 start Jan 2025 FDA feedback on next steps, • IPH6101 (CD123) ANKET ® Phase 2 Part
Slide 7: A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets
A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undiscl
Slide 8: ANKET Antibody-based NK cell Engager Therapeutics
& innate pharma w ANKET’ Antibody-based NK cell Engager Therapeutics
Slide 9: Proprietary NK cell engager platform
Proprietary NK cell engager platform Harness NK cells through Nkp46 NK-specific activating A fit-for-purpose technology receptor, conserved on Tumor infiltrating NK cells that is creating an entirely new class of tri- and tetra-specific molecules to induce synthetic immunity against cancer. MOAs : N
Slide 10: IPH6501: Innate's lead Proprietary ANKET, a novel CD20 targeted tetra-specific NK Cell Engager
IPH6501: Innate’s lead Proprietary ANKET®, a novel CD20 targeted tetra-specific Natural Killer Cell Engager targeting B-Cells IL-2v Tumor Associated Antigen • Provides proliferation signal targeted to NK cells • CD20 TAG NKp46 binder • NK cell activating receptor • Most specific marker of human NK c
Slide 11: IPH6501: Global Phase 1/2 dose finding study ongoing in R/R NHL
IPH6501: Global Phase 1/2 dose finding study patient recruitment currently ongoing in R/R NHL Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma Anti- CD20 NCT06088654 CD20 First patient dosed in March 2024 Recruitment ongoing 11
Slide 12: IPH6501: depletes autologous CD20+ B cells with greater efficacy and lower cytokine induction
IPH6501: depletes autologous CD20+ B cells from HD with greater efficacy and lower induction of pro-inflammatory cytokines than a CD20-TCE Stronger B cell depletion Less pro-inflammatory cytokines IPH6501 CD20-TCE IC-NKCE-IL2v Demaria et al., Science Immunology 2024 12
Slide 13: IPH6501: Potential is being recognized by external stakeholders
IPH6501: Potential is being recognized by external stakeholders Agreement with the Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be included in the ongoing Phase 1/2 trial 3m USD upfront plus up to 4.9m USD in conditional tranched investments from IFL
Slide 14: IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term
IPH6501: Multiple Clinical Milestones to be Delivered in Mid-term IPH6501 Phase 1/2 in B-NHL Safety data and preliminary Confirm activity and dose Readouts from expansion signals of activity in CD20+ optimization in CD20+ B-NHL studies in selected B-NHL B-NHL & select B-NHL subtypes subtypes (monoth
Slide 15: Antibody Drug Conjugates
B innate pharma . . Antibody Drug Conjugates <%) y Drug Conjug
Slide 16: IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC Phase 1 start in Jan 25 Payload Exatecan, Binder a Topoisomerase I inhibitor Proprietary humanized • Active in EV/MMAE-resistant models anti-Nectin-4 Antibody • Higher Bystander Effect than EV, • High affinity leading to stronger act
Slide 17: IPH4502: Differentiated Nectin-4 ADC for moderate to low expressing and Padcev resistant tumors
ADC IPH4502: A differentiated Nectin-4 targeted ADC with potential to show efficacy in moderate to low Nectin-4 expressing and Padcev resistant tumors OPPORTUNITIES 100 No Nectin-4 drug approved % of Nectin-4 expressing 80 • PADCEV (enfortumab vedotin, EV) is approved in bladder cancer where tumor s
Slide 18: IPH4502: Shows efficacy across various Nectin-4 expression levels
ADC IPH4502: Shows efficacy across various Nectin-4 expression levels and demonstrates superior activity to EV in bladder PDX models H-score: 300 H-score: 180 H-score: 100 Nectin-4 expression 2000 2000 2000 Vehicle Tumor volume (mm3) Tumor volume (mm3) Tumor volume (mm3) 1500 1500 1500 EV 4 mg/kg 10
Slide 19: IPH4502: In vivo efficacy in heterogeneous Nectin-4 tumors via bystander effect
ADC IPH4502: Demonstrates in vivo potential for efficacy in heterogenous Nectin-4 expressing tumors via target-dependent bystander effect Nectin-4+ cells Nectin-4 KO cells Nectin-4+ cells + Nectin-4 KO cells Tumor volume (mm3) In vivo bystander killing Address heterogeneous Nectin-4 expression 19
Slide 20: IPH4502: Anti-tumor activity in a PDX-model of acquired EV-resistance
ADC IPH4502: Anti-tumor activity in a PDX-model of acquired EV-resistance Efficacy in model of EV acquired resistance Address post-EV patients 20
Slide 21: IPH4502: Multiple Clinical Milestones to be Delivered in Mid-term
ADC IPH4502: Multiple Clinical Milestones to be Delivered in Mid-term IPH4502 Phase 1 in Nectin-4 expressing tumors Start basket trial in combination with SOC Preliminary safety and activity signal in tumor types with low Readout from dose Dose FPI in Phase 1 and high Nectin-4 expression expansions
Slide 22: Current Late Stage Assets
B innate pharma o-- (>>I J Current Late Stage Assets
Slide 23: Lacutamab: Phase 3 ready proprietary asset with path to accelerated FDA approval
lacutamab Lacutamab: Phase 3 ready proprietary asset with path to accelerated FDA approval Lacutamab under development for treatment of First-in-class anti-KIR3DL2 humanized Cutaneous T-cell lymphomas (CTCL) and Peripheral T Cell Lymphomas (PTCL). cytotoxicity-inducing antibody Phase 2 data in Sézar
Slide 24: Lacutamab: Phase 2 data in Sézary syndrome patients
lacutamab Lacutamab: Compelling Phase 2 data in Sézary syndrome patients with high unmet need and limited treatment options Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Patient characteristics 56 post mogamulizumab patients with advanced
Slide 25: Lacutamab: Strong Phase 2 results in heavily pretreated Mycosis fungoides
lacutamab Lacutamab: Strong Phase 2 results in heavily pretreated Mycosis fungoides Best Overall Response by KIR3DL2 Expression Level KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) Data cutoff: Oct 13, 2023 Patient characteristics (N=107) Efficacy results 4 median lines of prior therapy Olsen 2011 Global OR
Slide 26: Lacutamab: TELLOMAK data supports a potential new SoC in MF & SS
lacutamab Lacutamab: TELLOMAK data supports a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population All comers Earlier Line ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1% ≥ 1% ≥1 Pri
Slide 27: Lacutamab: Moving Towards Registrational Trial
lacutamab Lacutamab: Moving Towards Registrational Trial Phase 3 in CTCL Phase 3 readout CTCL Partnership AA submission discussions 2025 2026 2027 + Phase 2 KILT in PTCL PTCL PTCL Phase 2 data Data will inform next steps 27 CTCL: cutaneous T cell lymphome; AA: accelerated approval; PTCL: peripheral
Slide 28: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Monalizumab blocks the NKG2A • Three Phase 2 Trials supporting inhibitory receptor on both NK cells and rationale of combination in early cytotoxic CD8+ T cells. NSCLC -COAST -NeoCOAST -NeoCOAST-2 Durvalumab
Slide 29: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts Delivering across our strategic objectives IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 safety and preliminary efficacy data IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 clinical data Proprietary IPH4502 ADC (Nectin-4 ADC) | Phase 1 safety and IPH4502 ADC (Nectin-4 ADC) |
Slide 30: Key Takeaways
Key Takeaways Innate has a solid strategy to deliver long term growth with proprietary and partnered assets and we have 7 key programs in clinical stages of development • DRIVING FORWARD OUR ANKET® CLINICAL PORTFOLIO • Phase 1/2 clinical trial underway with IPH6501 in B-cell NHL, agreement with IFLI
Innate Pharma — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix